Renaissance Capital logo

Kiromic BioPharma Priced, Nasdaq: KRBP

Preclinical biotech developing immunotherapies for blood cancers and solid tumors.

Industry: Health Care

Latest Trade: $2.67 0.00 (0.0%)

First Day Return: -4.2%

Return from IPO: -77.8%

Industry: Health Care

We are a target discovery and gene editing company utilizing artificial intelligence and our proprietary neural network platform with a therapeutic focus on immuno-oncology. Our proprietary target discovery engine is called "Diamond." Diamond is a computational platform and a neural network that can identify new cancer immunological targets for T cells and B cells. Diamond is an artificial intelligence driven bioinformatic approach that can identify novel surface tumor targets. It uses public and proprietary samples and can expand into the tumor target space. Diamond generates a prioritized list of cancer immunological targets for T cells and B cells. These targets can be used to create therapies such as antibody therapies, T cell therapies, T cell receptor therapies, CAR T cell therapies and vaccine therapies. Using our proprietary technologies, we are researching and developing multiple product candidates for the treatment of blood cancers and solid tumors. Our product candidates are allogenic engineered cells to be used for specific patients or as off-the-shelf treatments for any patient with a particular cancer type. Each product candidate targets a selected antigen expressed on tumor cells and bears specific engineered attributes.
more less
IPO News for Kiromic BioPharma
more
IPO Data
IPO File Date 05/11/2020
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 1.3
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 10/15/2020
Offer Price $12.00
Price Range $12.00 - $14.00
Offer Shares (mm) 1.3
Deal Size ($mm) $15
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Houston, TX
Founded 2006
Employees 11
Website www.kiromic.com